Leading the Way in Life Science Technologies

GEN Exclusives

More »

Market and Technology Analysis

More »
Nov 6, 2013

Stem Cell Market: A Rapidly Expanding Field Ripe with Opportunities

This report based on a bottom-up industry analysis frames some of the metrics characterizing the stem cells marketplace.

Stem Cell Market: A Rapidly Expanding Field Ripe with Opportunities

Stem cells in action. [Select Biosciences]

  • The focus of this GEN Market & Tech analysis report is to characterize the stem cells marketplace based on the following classes of data, which we have been collecting as part of our industry analysis of this field:

    • Industry SWOT
    • Primary market data of markers used to characterize different cellular classes
    • Publications landscape

    Taken together, these data provide a backdrop for understanding the stem cells marketplace as it exists today.

    Highlights of this report:

    • This report from GEN and Select Biosciences frames some of the metrics characterizing the stem cells marketplace based on a bottom-up industry analysis.
    • The field is expanding and currently boasts north of $1 billion in product sales on a double-digit growth trajectory.
    • Both product and service models currently exist, and we expect this breakout to continue forward over the coming decade.
    • There are both autologous and allogeneic models that currently exist depending on disease class, type of cells utilized, route of administration, and ex vivo processing methodology.
    • From a product vendor perspective, the space is highly fragmented with a large number of companies in each market segment, and this space is therefore ripe for consolidation.

    CLICK HERE to download the PDF report.

  • Ask the Biotech Analyst

    Got a question about the stem cell marketplace? Dr. Razvi, co-author of this report, is available to answer your questions!

    Simply submit your question in the Readers' Comments box below by no later than Wednesday, November 13, and keep your eyes peeled for a special GEN News Highlight where we will present Dr. Razvi's answers!

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »